Clinical Trial Update: Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery [NA]

View source ↗

Summary

Clinical trial evaluating Gemcitabine hydrochloride, Cisplatin, and AGS-003-BLD for muscle-invasive bladder cancer undergoing surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• AGS-003-BLD
• CISPLATIN (cisplatin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: Mayo Clinic | Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma | NA | Status: WITHDRAWN